View Older Stories View More Recent Stories

Oct 20, 2021 05:42AM Merck (MRK) Announces Voluntary Nationwide Recall of CUBICIN 500mg, Due to Presence of Particulate Matter Identified as Glass Particles
Oct 19, 2021 07:30PM Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
Oct 15, 2021 07:20AM Merck (MRK), Eisai Receive Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Two Different Types of Cancer
Oct 15, 2021 07:20AM Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer
Oct 15, 2021 07:15AM Merck (MRK) Announces Positive CHMP Opinion for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Oct 15, 2021 07:15AM Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Oct 13, 2021 02:46PM Merck (MRK) Announces FDA Approves KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L
Oct 13, 2021 02:45PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Expres
Oct 12, 2021 09:00AM MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
Oct 12, 2021 06:51AM UPDATE: Merck (MRK) Commences Cash Tender Offer to Acquire Acceleron Pharma (XLRN) for $180/sh, Deal Announced on Sept. 30
Oct 12, 2021 06:45AM Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
Oct 11, 2021 06:00AM Merck (MRK) and Ridgeback Submit Emergency Use Authorization Application to the U.S. FDA for Molnupiravir
Oct 11, 2021 06:00AM Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate C
Oct 5, 2021 08:30AM  Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer
Oct 4, 2021 03:00AM EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021
Oct 1, 2021 06:04AM Merck (MRK) and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderat
Oct 1, 2021 06:00AM Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVI
Sep 30, 2021 06:46AM Merck (MRK) to Acquire Acceleron Pharma (XLRN) for $180 Per Share in $11.5 Billion Deal
Sep 30, 2021 06:45AM Merck to Acquire Acceleron Pharma Inc.
Sep 29, 2021 04:00PM Merck (MRK) Announces Appointment of Thomas H. Glocer as Independent Lead Director
Sep 29, 2021 04:00PM Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director
Sep 28, 2021 06:45AM Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
Sep 27, 2021 06:45AM Merck (MRK) Announces KEYTRUDA Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Sep 27, 2021 06:45AM Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Sep 24, 2021 06:45AM LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-R
Sep 20, 2021 05:41AM Merck's (MRK) KEYTRUDA Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma
Sep 19, 2021 06:22PM Merck's (MRK) KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% vs Chemotherapy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer Where Tumors Expressed PD-L1
Sep 19, 2021 07:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors
Sep 18, 2021 09:05AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
Sep 18, 2021 09:05AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persis
Sep 17, 2021 07:16AM Merck (MRK) Announces Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Br
Sep 17, 2021 07:15AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Ca
Sep 8, 2021 06:45AM Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
Sep 7, 2021 09:15AM Illumina (ILMN) Partners with Merck (MRK) to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
Sep 7, 2021 06:46AM Merck (MRK) KEYTRUDA® Approved in China in Combination With Chemotherapy Treatment of Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Sep 7, 2021 06:45AM Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
Sep 7, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesopha
Sep 1, 2021 06:45AM Merck (MRK) And Ridgeback Initiate Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
Sep 1, 2021 06:45AM Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
Aug 31, 2021 04:06PM FDA Approves Updated Indication for Merck's (MRK) KEYTRUDAfor Treatment of Certain Patients With Urothelial Carcinoma
Aug 31, 2021 04:05PM FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
Aug 26, 2021 06:50AM Merck (MRK) KEYTRUDA Receives Two New Approvals in Japan
Aug 26, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Aug 25, 2021 06:47AM Merck (MRK) Announces VAXNEUVANCE Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
Aug 25, 2021 06:45AM Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
Aug 20, 2021 04:46PM Merck (MRK) Announces Resignation of Leslie A. Brun from Board
Aug 20, 2021 04:45PM Leslie A. Brun Resigns from Merck Board of Directors
Aug 16, 2021 05:11AM Merck's (MRK) WELIREG™ (belzutifan) Approved by FDA for Treatment of Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
Aug 13, 2021 07:00PM FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumor
Aug 12, 2021 05:35AM FDA Approves Merck's (MRK) KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients with Advanced RCC
View More Recent Stories View Older Stories